| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cyclin-dependent kinases CDK1/cyclin B, CDK2, and CDK5. Butyrolactone I is an ATP-competitive inhibitor of CDK1 with an IC50 of 20 μg/ml in PC-14 cells. It inhibits the cell cycle at the G1/S and G2/M transitions and prevents phosphorylation of Rb and H1 histone.
|
|---|---|
| ln Vitro |
Butyrolactone I is a selective inhibitor of CDK1/cyclin B, CDK2, and CDK5. It inhibits Cdc2 of unsynchronized cultured prostate cancer cells and interrupts the cell cycle progression toward cell division. Inhibition of Cdc2 leads to accumulation of cells in the 4C phase without mitosis, resulting in accumulation of cyclin B1. Butyrolactone I exhibits antitumor activity.
|
| ln Vivo |
In vivo, butyrolactone I has been studied for its antitumor activity. It inhibits the cell cycle at the G1/S and G2/M transitions and exhibits antitumor activity. The compound induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for butyrolactone I involve measuring its inhibition of CDK1, CDK2, or CDK5 activity. CDK enzymes are incubated with histone H1 or other substrates and various concentrations of butyrolactone I. Kinase activity is measured by detecting phosphorylation of the substrate using radioactive or fluorescent methods. IC50 values are determined from concentration-response curves.
|
| Cell Assay |
In vitro cellular assays for butyrolactone I involve treating cancer cells (such as prostate cancer cells) with the compound and measuring cell cycle distribution, proliferation, and apoptosis. Cells are treated with various concentrations of butyrolactone I, and cell cycle analysis is performed by flow cytometry. Cell proliferation is assessed by MTT or other metabolic assays. Cyclin B1 and Rb phosphorylation are assessed by Western blot.
|
| Animal Protocol |
In vivo animal studies for butyrolactone I typically involve administration to xenograft models of cancer. Tumor-bearing mice are treated with butyrolactone I, and tumor growth inhibition is measured. The compound exhibits antitumor activity. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic properties.
|
| ADME/Pharmacokinetics |
Butyrolactone I has a molecular weight of 334.32 and a molecular formula of C17H18O7. It is a secondary metabolite from Aspergillus terreus. The compound is soluble in ethanol, methanol, DMF, and DMSO. It should be stored at 4°C. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of butyrolactone I are limited. The compound is a selective inhibitor of cyclin-dependent kinases and exhibits antitumor activity. Comprehensive toxicological evaluation is needed before clinical development. The compound should be handled with appropriate safety precautions.
|
| References |
|
| Additional Infomation |
Reports indicate that methyl 4-hydroxy-2-[[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]methyl]-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylic acid has been found in Aspergillus and Aspergillus terreus, and relevant data are available for reference.
Butyrolactone I is a secondary metabolite from Aspergillus terreus that acts as a selective inhibitor of cyclin-dependent kinases CDK1/cyclin B, CDK2, and CDK5. It inhibits the cell cycle at the G1/S and G2/M transitions and exhibits antitumor activity. Butyrolactone I induces cyclin B1 and causes G2/M arrest in human prostate cell lines. It is a valuable research tool for studying CDK function and cell cycle regulation. |
| Molecular Formula |
C24H24O7
|
|---|---|
| Molecular Weight |
424.4432
|
| Exact Mass |
424.152
|
| CAS # |
87414-49-1
|
| PubChem CID |
5235506
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.342g/cm3
|
| Boiling Point |
661.1ºC at 760 mmHg
|
| Flash Point |
228ºC
|
| Index of Refraction |
1.633
|
| LogP |
3.586
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
743
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCC1=C(C=CC(=C1)C[C@]2(C(=C(C(=O)O2)O)C3=CC=C(C=C3)O)C(=O)OC)O)C
|
| InChi Key |
NGOLMNWQNHWEKU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H24O7/c1-14(2)4-6-17-12-15(5-11-19(17)26)13-24(23(29)30-3)20(21(27)22(28)31-24)16-7-9-18(25)10-8-16/h4-5,7-12,25-27H,6,13H2,1-3H3
|
| Chemical Name |
methyl 4-hydroxy-2-[[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]methyl]-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~235.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3560 mL | 11.7802 mL | 23.5605 mL | |
| 5 mM | 0.4712 mL | 2.3560 mL | 4.7121 mL | |
| 10 mM | 0.2356 mL | 1.1780 mL | 2.3560 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
